These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16621589)

  • 21. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
    [No Abstract]   [Full Text] [Related]  

  • 24. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating dyslipidemic patients with lipid-modifying and combination therapies.
    Worz CR; Bottorff M
    Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
    Windler E; Schöffauer M; Zyriax BC
    Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).
    Wong ND; Chuang J; Wong K; Pham A; Neff D; Marrett E
    Am J Cardiol; 2013 Aug; 112(3):373-9. PubMed ID: 23642513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
    Pintó X
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG
    Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.
    Sukonthasarn A; Homsanit M; Prommete B; Chotinaiwattarakul C; Piamsomboon C; Likittanasombat K
    J Med Assoc Thai; 2011 Dec; 94(12):1424-34. PubMed ID: 22295727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.